-
![Glass Vial, medication powder-GettyImages-876484700]( "When Lyophilization Fails At Scale, First Scrutinize Your Formulation")
When Lyophilization Fails At Scale, First Scrutinize Your FormulationWhen lyophilizing a challenging biologic drug product, use an integrated approach optimizing formulation and process parameters together.
-
![hand holding vial-GettyImages-951661874]( "The 5 Shifts That Could Remake Lyophilization By 2040")
The 5 Shifts That Could Remake Lyophilization By 2040Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
-
![DMAIC, Define, Measure, Analyze, Improve, Control-GettyImages-2103944843]( "Your 7 Decisions To Make Before MES Configuration")
Your 7 Decisions To Make Before MES ConfigurationDon't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
-
![Finding the hidden costs-GettyImages-1478035639]( "DEA Reveals Hidden Costs Of Analytical Validation Guidelines")
DEA Reveals Hidden Costs Of Analytical Validation GuidelinesBy treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
![Quality assurance, approved network-GettyImages-2247428372]( "Qualification And Validation Of Depyrogenation Tunnels And Autoclaves")
Qualification And Validation Of Depyrogenation Tunnels And AutoclavesSystemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
![FDA-GettyImages-2271213876]( "FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters")
FDA Modernizes Container Closure Guidance: What Is Changing And Why It MattersThe proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
![Water droplets, PFAS, Forever chemical water contamination-GettyImages-2173433890]( "Characterization Of PFAS Extractables In Gas Filtration Devices")
Characterization Of PFAS Extractables In Gas Filtration DevicesUnderstand how fluorinated membrane chemistries in sterilizing grade gas filters may introduce PFAS risks, and how extractables testing can support contamination control strategies.
-
![GettyImages-1437855768-lipid-nanoparticle-lnp-mrna vaccine]( "High-Performing Ionizable Lipids For Controlled Nucleic Acid Delivery")
High-Performing Ionizable Lipids For Controlled Nucleic Acid DeliveryIonizable lipids are central to effective mRNA delivery, influencing potency, biodistribution, and toxicity. See why advancing delivery beyond the liver will require stronger structure-function insights.
-
![CAPA effectiveness-GettyImages-2283083181]( "You Can't CAPA What You Can't Classify")
You Can't CAPA What You Can't ClassifyAn LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
![Getty Images-823447656-vector-viral-lab-AAV-cell-development]( "Transforming Gene Therapy With A Scalable Platform Solution")
Transforming Gene Therapy With A Scalable Platform SolutionDiscover how a platform approach to AAV manufacturing can reduce development time and cost, as well as how optimized processes enable reliable production and scalable implementation in bioreactors.
-
![complex messy management, bureaucracy,red tape,organization, communication problems,business disruption-GettyImages-2262947509]( "6 Modeling Approaches That Make Complex Bioprocess Data Useful")
6 Modeling Approaches That Make Complex Bioprocess Data UsefulAI algorithms can reduce data dimensionality more faithfully by interpreting multivariate features relevant to prediction or control.
-
![GettyImages-1316008775 ion chromatography lab]( "Chromatography Polishing Under Pressure: New Demands")
Chromatography Polishing Under Pressure: New DemandsUpstream productivity gains and evolving antibody formats are raising the bar for chromatography polishing, making it a more consequential variable in downstream process design.
-
![AI, artificial intelligence, medicine technology, digital transformation-GettyImages-2276984949]( "Reliability In Bioprocessing Is Your Competitive Advantage")
Reliability In Bioprocessing Is Your Competitive AdvantageEquipment reliability is a prerequisite for realizing value from digital transformation, automation, and data-driven initiatives in bioprocess manufacturing.
-
![Artifical intelligence, future concept-GettyImages-1166228181]( "Building Trust In AI For Computerized System Validation")
Building Trust In AI For Computerized System ValidationUsing AI for CSV might feel like the students are grading their own papers. One consultant explains why it's not the same, namely, there are no subjective judgment calls.
-
![data search, information discovery, file management, digital analysis, and advanced data retrieval systems-GettyImages-2284270263]( "Controls For Retrieval-Augmented Generation In GxP")
Controls For Retrieval-Augmented Generation In GxPValidation teams deal with inherent variability all the time. The same principles for GMP — think visual inspection — can apply to probabilistic AI systems.
ABOUT BIOSIMILAR MANUFACTURING
Biosimilars are considered to be low-cost substitutions for pricy, large-molecule biologics. However, biosimilars must meet the same quality, safety, and efficacy as their reference biologic. Manufacturing biosimilars requires a more complicated procedure than that of manufacturing small molecule generics. Companies manufacturing biosimilars are focused on creating a chemical structure that is as close as possible to that of the reference product. Failure rates and operational costs pose a challenge for those companies involved in manufacturing biosimilars compared to those manufacturing small molecule generics.
Small molecule generics are created using the same active pharmaceutical ingredient (API) and, therefore, are chemically identical to that of the originator medicine. The manufacturing process for small molecules comprises only one-fifth of the total in-process tests required to meet Good Manufacturing Practice compared to that of biologic medicines (50 vs. 250 in-process tests). In fact, the manufacturing process for a large molecule is so complex, it cannot be duplicated by two different manufacturers, as the cells used in biologic medicines are unique to the company manufacturing each biologic.
Manufacturing a biologic consists of genetically modifying a cell, which becomes the basis for a cell line used for the production of the necessary protein for the biologic medicine. The protein is then separated from the cells and purified. Biosimilars are created from small alterations to the manufacturing process which creates a molecule that is not identical but closely resembles the reference product. While the differences in the biosimilar molecule might be slight, these changes in the manufacturing process of a biosimilar can affect the efficacy and safety of a biosimilar compared to the reference biologic. Over the past decade, the manufacturing process for proteins has become more standardized and the required technology has become increasingly accessible, leading to reductions in biosimilars production costs. As a result, a greater number of companies have begun manufacturing biosimilars, while reference brand manufacturers are setting their sights on bolstering pipelines and manufacturing biobetters to maintain market share for their soon-to-be-off-patent reference products.
BIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Generic Medicines Manufacturers Ramp Up Patch Supply To Meet Demand
- Formycon And Zydus: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
- Xbrane Announces Full Recruitment Of Pivotal Clinical Trial For Xdivane
- Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- And Short-Acting G-CSF Options